Tag Archives: AXSM

Best Clean Energy Stocks To Invest In Right Now

Freshman Congress member Alexandria Ocasio-Cortez and veteran lawmaker Sen. Edward Markey are introducing a resolution spelling out congressional support for a Green New Deal — an ambitious plan to remake the U.S. economy and drastically reduce the nation’s greenhouse gas emissions.

The resolution largely sticks to a blueprint Ocasio-Cortez laid out when she proposed creating a House select committee to establish a Green New Deal. That framework called for generating 100 percent of the nation’s power from renewable sources, making all buildings energy efficient and eliminating carbon dioxide and other greenhouse gas emissions from the transportation sector and industry — all within about 10 years.

The plan also proposes massive investments in research and development to make the U.S. a leader in clean energy technology. In addition, the Green New Deal envisioned by Ocasio-Cortez aims to implement progressive policies such as a federal jobs guarantee, basic income and universal health care.

Best Clean Energy Stocks To Invest In Right Now: Asbury Automotive Group Inc(ABG)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Arizona State Retirement System lifted its position in shares of Asbury Automotive Group, Inc. (NYSE:ABG) by 2.2% in the fourth quarter, Holdings Channel reports. The fund owned 30,187 shares of the company’s stock after buying an additional 662 shares during the period. Arizona State Retirement System’s holdings in Asbury Automotive Group were worth $2,012,000 at the end of the most recent quarter.

  • [By Jon C. Ogg]

    Asbury Automotive Group Inc. (NYSE: ABG) was raised to Equal Weight from Underweight at Morgan Stanley, which also raised the price target to $71 from $63. Asbury shares previously closed at $72.40, but they were down 1.1% at $71.60 on Tuesday morning. The 52-week trading range is $49.10 to $76.50, and the previous consensus analyst target price was $75.86.

  • [By Logan Wallace]

    Asbury Automotive Group (NYSE:ABG) will post its quarterly earnings results before the market opens on Wednesday, February 6th. Analysts expect Asbury Automotive Group to post earnings of $2.06 per share for the quarter.

  • [By Lisa Levin] Companies Reporting Before The Bell
    United Technologies Corporation (NYSE: UTX) is estimated to report quarterly earnings at $1.51 per share on revenue of $14.62 billion.
    The Coca-Cola Company (NYSE: KO) is expected to report quarterly earnings at $0.46 per share on revenue of $7.31 billion.
    Caterpillar Inc. (NYSE: CAT) is projected to report quarterly earnings at $2.07 per share on revenue of $11.93 billion.
    Verizon Communications Inc. (NYSE: VZ) is expected to report quarterly earnings at $1.11 per share on revenue of $31.22 billion.
    Lockheed Martin Corporation (NYSE: LMT) is estimated to report quarterly earnings at $3.42 per share on revenue of $11.28 billion.
    The Sherwin-Williams Company (NYSE: SHW) is projected to report quarterly earnings at $3.15 per share on revenue of $3.94 billion.
    Biogen Inc. (NASDAQ: BIIB) is expected to report quarterly earnings at $5.92 per share on revenue of $3.15 billion.
    3M Company (NYSE: MMM) is estimated to report quarterly earnings at $2.52 per share on revenue of $8.26 billion.
    JetBlue Airways Corporation (NASDAQ: JBLU) is projected to report quarterly earnings at $0.2 per share on revenue of $1.75 billion.
    Eli Lilly and Company (NYSE: LLY) is expected to report quarterly earnings at $1.13 per share on revenue of $5.49 billion.
    Harley-Davidson, Inc. (NYSE: HOG) is estimated to report quarterly earnings at $0.88 per share on revenue of $1.25 billion.
    Corning Incorporated (NYSE: GLW) is expected to report quarterly earnings at $0.3 per share on revenue of $2.50 billion.
    Centene Corporation (NYSE: CNC) is projected to report quarterly earnings at $1.88 per share on revenue of $13.28 billion.
    The Travelers Companies, Inc. (NYSE: TRV) is estimated to report quarterly earnings at $2.77 per share on revenue of $6.75 billion.
    Wipro Limited (NYSE: WIT) is expected to report quarterly earnings at $0.07 per share on revenue of $2.16 billion.
    PACCAR Inc (NASDAQ: PCAR) is projected to
  • [By Rich Smith]

    The three car dealers SunTrust reviewed this morning are Asbury Automotive Group (NYSE:ABG), AutoNation (NYSE:AN), and Penske Automotive Group (NYSE:PAG).

  • [By Jon C. Ogg]

    Asbury Automotive Group Inc. (NYSE: ABG) was started as Hold and assigned a $78 target price (versus a $75.75 close) at SunTrust Robinson Humphrey.

Best Clean Energy Stocks To Invest In Right Now: Crestwood Equity Partners LP(CEQP)

Advisors’ Opinion:

  • [By Reuben Gregg Brewer]

    For example, relatively small peer Crestwood Equity Partners LP (NYSE:CEQP) ended the month up 13%. ONEOK (NYSE:OKE), which is structured as a regular corporation and not a limited partnership, rose an impressive 19%. And Canadian midstream owner Pembina Pipeline (NYSE:PBA) jumped 20% (like ONEOK, Pembina is not structured as a limited partnership). The midstream sector across the board had a pretty decent month.

  • [By Shane Hupp]

    Luzich Partners LLC raised its position in shares of Crestwood Equity Partners LP (NYSE:CEQP) by 5.2% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 581,601 shares of the pipeline company’s stock after acquiring an additional 28,640 shares during the period. Crestwood Equity Partners makes up about 14.6% of Luzich Partners LLC’s investment portfolio, making the stock its 2nd largest position. Luzich Partners LLC’s holdings in Crestwood Equity Partners were worth $14,889,000 at the end of the most recent reporting period.

  • [By Matthew DiLallo]

    Crestwood Equity Partners (NYSE:CEQP), Oasis Midstream Partners (NYSE:OMP), and Hess Midstream Partners (NYSE:HESM) are far from household names. Because of that, most investors probably missed the fact that these high-yielding master limited partnerships (MLPs) have been red-hot this year. However, while all have delivered strong returns in 2018, each one still has plenty of fuel left in the tank to continue providing outsized gains in the coming years, which is why investors won’t want to keep overlooking the potential of these pipeline companies.

Best Clean Energy Stocks To Invest In Right Now: Axsome Therapeutics, Inc.(AXSM)

Advisors’ Opinion:

  • [By Max Byerly]

    Axsome Therapeutics (NASDAQ:AXSM) released its quarterly earnings results on Tuesday. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.09, Bloomberg Earnings reports.

  • [By Lisa Levin] Gainers
    Comstock Resources, Inc. (NYSE: CRK) shares shot up 52 percent to $7.235 after the company disclosed a deal with Arkoma Drilling L.P. and Williston Drilling, L.P. to buy oil & gas properties in North Dakota. Comstock announced withdrawal of tender offers for outstanding secured notes.
    MarineMax, Inc. (NYSE: HZO) shares gained 24.2 percent to $21.80 as the company posted upbeat Q2 results and raised its FY18 outlook.
    Mattersight Corporation (NASDAQ: MATR) shares rose 22 percent to $2.625 after the company agreed to be purchased by NICE Ltd.
    Chipotle Mexican Grill, Inc. (NYSE: CMG) jumped 21.3 percent to $411.871 as the company reported stronger-than-expected results for its first quarter on Wednesday.
    Axsome Therapeutics, Inc. (NASDAQ: AXSM) rose 17 percent to $3.10 after the company disclosed a positive outcome of the interim analysis of STRIDE-1 Phase 3 trial of AXS-05 in treatment resistant depression.
    Ultra Clean Holdings, Inc. (NASDAQ: UCTT) rose 15.9 percent to $18.34 following upbeat Q1 earnings.
    PCM, Inc. (NASDAQ: PCMI) gained 15.6 percent to $12.20 following Q1 results.
    O'Reilly Automotive, Inc. (NASDAQ: ORLY) surged 14.4 percent to $260.3901 following upbeat Q1 profit.
    Concord Medical Services Holdings Limited (NYSE: CCM) gained 13.8 percent to $3.70.
    Penn National Gaming, Inc. (NASDAQ: PENN) rose 13.5 percent to $29.815 after reporting strong Q1 results.
    BioTelemetry, Inc. (NASDAQ: BEAT) rose 13.5 percent to $38.30 as the company reported stronger-than-expected earnings for its first quarter.
    Advanced Micro Devices, Inc. (NASDAQ: AMD) shares rose 13.1 percent to $10.985 as the company reported upbeat results for its first quarter.
    SJW Group (NYSE: SJW) shares gained 11.8 percent to $63.59 following Q1 results. California Water Service Group made an offer for SJW.
    Churchill Downs Incorporated (NASDAQ: CHDN) climbed 9.8 percent to $278.40 following Q1 results.
    CYS Investments, Inc. (NYSE: CYS)
  • [By Lisa Levin] Gainers
    Genprex, Inc. (NASDAQ: GNPX) shares gained 86.76 percent to close at $11.00 on Thursday.
    Comstock Resources, Inc. (NYSE: CRK) shares climbed 47.06 percent to close at $7.00 after the company disclosed a deal with Arkoma Drilling L.P. and Williston Drilling, L.P. to buy oil & gas properties in North Dakota. Comstock announced withdrawal of tender offers for outstanding secured notes.
    Ceridian HCM Holding Inc. (NASDAQ: CDAY) gained 41.86 percent to close at $31.21.
    MarineMax, Inc. (NYSE: HZO) shares rose 26.5 percent to close at $22.20 as the company posted upbeat Q2 results and raised its FY18 outlook.
    Concord Medical Services Holdings Limited (NYSE: CCM) jumped 24.92 percent to close at $4.06.
    Mattersight Corporation (NASDAQ: MATR) shares climbed 23.26 percent to close at $2.65 after the company agreed to be purchased by NICE Ltd.
    Chipotle Mexican Grill, Inc. (NYSE: CMG) rose 24.44 percent to close at $422.50 as the company reported stronger-than-expected results for its first quarter on Wednesday.
    Ultra Clean Holdings, Inc. (NASDAQ: UCTT) gained 17.75 percent to close at $18.64 following upbeat Q1 earnings.
    PCM, Inc. (NASDAQ: PCMI) rose 16.59 percent to close at $12.30 following Q1 results.
    Zymeworks Inc. (NASDAQ: ZYME) rose 16.06 percent to close at $15.25.
    Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) shares climbed 14.5 percent to close at $121.42 as the company posted reported Q1 beat And raised FY18 outlook.
    Advanced Micro Devices, Inc. (NASDAQ: AMD) shares gained 13.7 percent to close at $11.04 as the company reported upbeat results for its first quarter.
    Axsome Therapeutics, Inc. (NASDAQ: AXSM) rose 13.21 percent to close at $3.00 after the company disclosed a positive outcome of the interim analysis of STRIDE-1 Phase 3 trial of AXS-05 in treatment resistant depression.
    O'Reilly Automotive, Inc. (NASDAQ: ORLY) jumped 13.06 percent to close at $257.40 following upbeat Q1 profit.
    BioTelemetry,
  • [By Lisa Levin] Gainers
    Axsome Therapeutics, Inc. (NASDAQ: AXSM) rose 22.6 percent to $3.25 in pre-market trading after the company disclosed a positive outcome of the interim analysis of STRIDE-1 Phase 3 trial of AXS-05 in treatment resistant depression.
    Mattersight Corporation (NASDAQ: MATR) shares rose 23.2 percent to $2.65 in pre-market trading after the company agreed to be purchased by NICE Ltd.
    Comstock Resources, Inc. (NYSE: CRK) rose 21.2 percent to $5.77 in pre-market trading after the company disclosed a deal to buy oil & gas properties in North Dakota from Arkoma, Williston Drilling for about $620 million. The company also announced withdrawal of tender offers for outstanding secured notes.
    Chipotle Mexican Grill, Inc. (NYSE: CMG) rose 13.7 percent to $386.00 in pre-market trading as the company reported stronger-than-expected results for its first quarter on Wednesday.
    Quantenna Communications, Inc. (NASDAQ: QTNA) shares rose 12.6 percent to $14.70 in pre-market trading. Quantenna is expected to release Q1 results on April 30..
    BioTelemetry, Inc. (NASDAQ: BEAT) rose 11.1 percent to $37.50 in pre-market trading as the company reported stronger-than-expected earnings for its first quarter.
    Penn National Gaming, Inc. (NASDAQ: PENN) rose 10.4 percent to $29.00 in pre-market trading after reporting strong Q1 results.
    O'Reilly Automotive, Inc. (NASDAQ: ORLY) rose 9.8 percent to $250.00 in pre-market trading following upbeat Q1 profit.
    Advanced Micro Devices, Inc. (NASDAQ: AMD) shares rose 9.4 percent to $10.62 in pre-market trading as the company reported upbeat results for its first quarter.
    CYS Investments, Inc. (NYSE: CYS) rose 9.1 percent to $7.22 in pre-market trading after the company agreed to be acquired by Two Harbors Investment Corp (NYSE: TWO).
    GNC Holdings, Inc. (NYSE: GNC) rose 8.3 percent to $4.18 in pre-market trading after reporting Q1 results.
    Domino's Pizza, Inc. (NYSE: DPZ) shares rose 7.6 percent to $251.2
  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Axsome Therapeutics (AXSM)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Paul Ausick]

    Axsome Therapeutics Inc. (NASDAQ: AXSM) traded down about 43% Tuesday and posted a new 52-week low of $3.20 after closing Monday at $5.55. The 52-week high is $6.45. Volume was about 3.8 million, about 19 times the daily average of around 220,000 shares. The company will stop a “futile” portion of a trial of its treatment for knee osteoarthritis.

Best Clean Energy Stocks To Invest In Right Now: Sage Therapeutics, Inc.(SAGE)

Advisors’ Opinion:

  • [By Shane Hupp]

    SG Americas Securities LLC acquired a new position in SAGE Therapeutics Inc (NASDAQ:SAGE) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 5,233 shares of the biopharmaceutical company’s stock, valued at approximately $843,000.

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Maxx Chatsko]

    After sliding 41.8% in 2018, shares of Sage Therapeutics (NASDAQ:SAGE) jumped nearly 49% last month, according to data from S&P Global Market Intelligence. The sudden leap came after the company reported impressive results for SAGE-217 in a phase 3 trial studying the drug candidate as a potential treatment for postpartum depression.

  • [By Joseph Griffin]

    Stevens Capital Management LP bought a new stake in shares of SAGE Therapeutics Inc (NASDAQ:SAGE) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 3,223 shares of the biopharmaceutical company’s stock, valued at approximately $504,000.

  • [By ]

    Sage Therapeutics (SAGE) : “Let’s wait and see. I can’t bless it until I see more from them.”

    AbbVie (ABBV) : “I want to stay away from controversy. I like Eli Lilly (LLY) .”

  • [By Dan Caplinger]

    Friday was a poor day on Wall Street, as the Dow Jones Industrials fell 200 points and other major benchmarks lost about 1%. Rising bond yields were a major source of consternation among those following the financial markets, with the 10-year Treasury hitting 2.95% and helping to send mortgage rates sharply higher. Even though earnings season has gone fairly well for many companies, some investors are also starting to realize that political issues are likely to cloud the outlook for the U.S. economy in the coming months, creating more uncertainty that could stymie further market gains. Some bad news affecting individual companies also added to the negative mood. Stanley Black & Decker (NYSE:SWK), ManpowerGroup (NYSE:MAN), and Sage Therapeutics (NASDAQ:SAGE) were among the worst performers on the day. Here’s why they did so poorly.

Best Clean Energy Stocks To Invest In Right Now: Marsh & McLennan Companies, Inc.(MMC)

Advisors’ Opinion:

  • [By Max Byerly]

    Marsh & McLennan Companies (NYSE: MMC) and Kering (OTCMKTS:PPRUY) are both large-cap finance companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Marsh & McLennan Companies (MMC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Enlightenment Research LLC acquired a new position in Marsh & McLennan Companies, Inc. (NYSE:MMC) during the 4th quarter, HoldingsChannel reports. The fund acquired 800 shares of the financial services provider’s stock, valued at approximately $64,000.

  • [By Shane Hupp]

    Marsh & McLennan Companies (NYSE:MMC) had its price target reduced by equities research analysts at Citigroup from $100.00 to $98.00 in a note issued to investors on Thursday. The firm presently has a “buy” rating on the financial services provider’s stock. Citigroup’s price objective would suggest a potential upside of 15.01% from the company’s previous close.

  • [By Logan Wallace]

    Marsh & McLennan Companies, Inc. (NYSE:MMC) has received an average recommendation of “Hold” from the eleven brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $91.86.

Best Clean Energy Stocks To Invest In Right Now: MetLife, Inc.(MET)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Here are some of the news headlines that may have impacted Accern Sentiment’s analysis:

    Get MetLife alerts:

    Ultimate Stock-Pickers: Top 10 Buys and Sells (finance.yahoo.com) MetLife: Why investors should pay close attention to the… (finance.yahoo.com) Goldman Sachs Group Lowers MetLife (MET) to Neutral (americanbankingnews.com) Review: Morgan Wallen rocks MetLife Stadium, opens for Luke Bryan (digitaljournal.com) Goldman Sachs Downgrades MetLife (MET) to Neutral (streetinsider.com)

    Several equities research analysts recently issued reports on MET shares. Zacks Investment Research downgraded shares of MetLife from a “hold” rating to a “sell” rating in a research note on Tuesday, March 20th. Bank of America started coverage on shares of MetLife in a research note on Monday, March 26th. They set a “neutral” rating and a $50.00 price target on the stock. Atlantic Securities raised shares of MetLife from a “neutral” rating to an “overweight” rating in a research note on Monday, March 26th. Wells Fargo & Co reaffirmed a “buy” rating and set a $60.00 price target on shares of MetLife in a research note on Thursday, March 1st. Finally, Morgan Stanley dropped their price target on shares of MetLife from $58.00 to $56.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 5th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $56.81.

  • [By Lisa Levin] Gainers
    Cara Therapeutics, Inc. (NASDAQ: CARA) rose 18.2 percent to $13.71 in pre-market trading. Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma entered into ex-U.S. licensing agreement to commercialize KORSUVA™ injection in dialysis patients with pruritus.
    Heat Biologics, Inc. (NASDAQ: HTBX) shares rose 10.6 percent to $2.20 in pre-market trading after surging 12.43 percent on Tuesday.
    VAALCO Energy, Inc. (NYSE: EGY) rose 10.5 percent to $2.37 in pre-market trading after dropping 10.04 percent on Tuesday.
    Boxlight Corporation (NASDAQ: BOXL) rose 8.3 percent to $7.15 in pre-market trading after falling 16.03 percent on Tuesday.
    Tiffany & Co. (NYSE: TIF) rose 7.8 percent to $110.25 in pre-market trading after the company reported upbeat results for its first quarter and raised its FY2018 earnings guidance.
    Heat Biologics, Inc. (NASDAQ: HTBX) shares rose 7.1 percent to $2.13 in pre-market trading. after climbing 12.43 percent on Tuesday.
    Clementia Pharmaceuticals Inc. (NASDAQ: CMTA) rose 5.9 percent to $20.01 in pre-market trading after reporting positive Phase 2 Part B data showing treatment with palovarotene significantly reduces new bone growth in patients with FOP.
    Under Armour, Inc. (NYSE: UA) rose 3.5 percent to $18.44 in pre-market trading.
    Aegean Marine Petroleum Network Inc. (NYSE: ANW) shares rose 3.5 percent to $2.95 in pre-market trading.
    MetLife, Inc. (NYSE: MET) rose 3.2 percent to $50.00 in pre-market trading after reporting a $1.5 billion buyback plan.
    Lowe's Companies, Inc. (NYSE: LOW) rose 3.2 percent to $88.51 in pre-market trading. Lowe's reported downbeat results for its first quarter on Wednesday.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Shane Hupp]

    Salem Investment Counselors Inc. lifted its holdings in Metlife Inc (NYSE:MET) by 5.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,080 shares of the financial services provider’s stock after buying an additional 2,050 shares during the period. Salem Investment Counselors Inc.’s holdings in Metlife were worth $1,835,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By Max Byerly]

    Brookstone Capital Management reduced its stake in shares of Metlife Inc (NYSE:MET) by 3.1% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 108,058 shares of the financial services provider’s stock after selling 3,447 shares during the period. Brookstone Capital Management’s holdings in Metlife were worth $4,711,000 at the end of the most recent quarter.

  • [By Logan Wallace]

    State Treasurer State of Michigan lessened its stake in shares of MetLife (NYSE:MET) by 1.1% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 305,185 shares of the financial services provider’s stock after selling 3,300 shares during the period. State Treasurer State of Michigan’s holdings in MetLife were worth $14,005,000 as of its most recent SEC filing.

  • [By Ethan Ryder]

    Putnam Investments LLC increased its position in shares of Metlife Inc (NYSE:MET) by 1,847.7% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 523,396 shares of the financial services provider’s stock after purchasing an additional 496,523 shares during the quarter. Putnam Investments LLC owned 0.05% of Metlife worth $22,820,000 as of its most recent filing with the SEC.

Top 10 Stocks To Watch For 2018

Your Pizza Hut delivery could one day arrive via a self-driving Toyota van.

Toyota unveiled a concept vehicle called e-Palette, which could host a mobile store, act as a ride-sharing service or deliver packages. The announcement was unveiled at International CES in Las Vegas on Monday.

The automaker said it is teaming up with a handful of partners, including Pizza Hut, Amazon, Chinese ridesharing giant Didi and Uber.

“Today, you have to travel to the stores,” Toyota president Akio Toyoda said at the event. “In the future with e-Pallete, the store will come to you.”

Although e-Palette is only a concept vehicle for now, he added that the company plans to pilot the technology at the 2020 Olympic Games in Tokyo. Tests in the U.S. and other areas are envisioned for the early 2020s.

Introducing the first Pizza Hut fully autonomous delivery concept vehicle. Excited for our future with @Toyota #CES2018 pic.twitter.com/YGNQUgijha

Top 10 Stocks To Watch For 2018: Valeant Pharmaceuticals International Inc(VRX)

Advisors’ Opinion:

  • [By Chris Lange]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) sawits shares hit a multiyear low this past week. There was hope for a turnaround when Joe Papa took over as chief executive officer,but it seems that littlehas gone his way, especially after the company reported earnings early this week. Some analysts took this opportunity to reevaluate their stance on the stock. Although this might be a buy for some, the returns look to be getting smaller.

  • [By Paul Ausick]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped about 6.2% Friday, to post a new 52-week low of $12.90 after closing at $13.75 on Thursday. The stock’s 52-week high is $70.43. Volume was about double the daily average of around 15.9 million shares. The company completed the sale of some skincare brands to L’Or茅al.

  • [By Chris Lange]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) made waves early on Tuesday after the company offered a plethora of announcements. First the company gave an update on its late-stage psoriasis trial. Along with this success, Valeant reported the sale of a couple of its business segments, bringing in a sizable amount of cash.

  • [By Kumar Abhishek] Valeant Pharmaceuticals(NYSE:VRX) stock jumps after the company sold Dendreon for hefty gains.
    Flickr

    Shares of Valeant (NYSE:VRX) jumped more than 14% in pre-market trading yesterday, after the Canadian drug maker announced its long-awaited asset sale plans. The stock later gave away some of its gains after Moody’s released a report stating that the asset sales will not impact its credit rating or outlook, though Valeant’s bond prices jumped by 4.5%. Valeant is a classic example of a shareholder value destroyer. Once the darling of Wall Street, the stock has lost more than 90% of its value since its peak in 2014 and is down by more 80% in the last one year. The stock has dragged portfolios of the likes of Bill Ackman and Prof. Aswath Damodaran. However, the asset saleprovides a ray of hope for Valeant’s shareholders.

  • [By WWW.THESTREET.COM]

    Bond prices were much lower early in the day, with yields up by nearly 10 basis points. But fixed income has rallied back (reducing the drop by half on the day). Valeant Pharmaceuticals (VRX) , more weakness. Large pharma lower, led by Eli Lilly (LLY) . Old tech lags, with International Business Machines (IBM) , Intel (INTC) , Cisco Systems (CSCO) and Microsoft (MSFT) all lower. Media roughed up a bit (CBS (CBS) and Comcast (CMCSA) ). The Ugly
    Gold down another $23 to $1,188 (SPDR Gold Trust ETF (GLD) down $2.25). Urban Outfitters (URBN) down $5. NOTE: There will be no “Takeaways” today!   Happy Thanksgiving. Position: Long GLD small, SDS large, JCP large; short SPY, CSCO, CAT small, IWM, TLT small.

  • [By Wayne Duggan]

    Market laggards that could come under additional window dressing selling pressure include Valeant Pharmaceuticals Intl Inc (NYSE: VRX), Endo International plc – Ordinary Shares (NASDAQ: ENDP) and NewLink Genetics Corp (NASDAQ: NLNK).

Top 10 Stocks To Watch For 2018: CVR Refining, LP(CVRR)

Advisors’ Opinion:

  • [By Tyler Crowe]

    For refiners, though, that spread in price led to very lucrative refining margins. As that spread has narrowed, so too has margins for refiners.

    Refining Margins Q4 2012 Q2 2013
    Valero (NYSE: VLO  ) $12.27 $9.26
    Phillips 66 (NYSE: PSX  ) $13.67 $9.88
    HollyFrontier (NYSE: HFC  ) $24.00 $20.28
    CVR Refining (NYSE: CVRR  ) $28.08 $20.30

    Source: Company Earnings releases

  • [By Robert Rapier]

    CVR Partners’ fertilizer plant is located in Coffeyville, Kansas, adjacent to the refinery owned by CVR Refining (NYSE: CVRR). CVR Energy (NYSE: CVI), majority-owned by Carl Icahn via Icahn Enterprises (NYSE: IEP), is the general partner and owns most of the units for both CVR Partners and CVR Refining.

  • [By Lisa Levin]

    Shares of CVR Refining LP (NYSE: CVRR) were down 11 percent to $10.00. Velocity Midstream Partners and CVR Refining disclosed the execution of agreements related to the construction of a crude oil pipeline from the SCOOP play in Central Oklahoma to CVR's Wynnewood refinery.

Top 10 Stocks To Watch For 2018: Euro/Yen(EJ)

Advisors’ Opinion:

  • [By Belinda Cao]

    E-House China Holdings Ltd. (EJ), a real estate brokerage, gained 9.2 percent to $9.70, extending it advance to a third week. Its American depositary receipts retreated 3.1 percent Sept. 20 from the highest level since May 2011.

Top 10 Stocks To Watch For 2018: Brink's Company (The)(BCO)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    World Wrestling Entertainment (NYSE: WW) received a pair of downgrades after its earnings report came in below estimates.

    Sell-Side's Most Noteworthy Calls
    Baird downgraded Cardinal Health (NYSE: CAH) to Neutral.
    Imperial downgraded Brinks (NYSE: BCO) to In-Line.
    Jefferies upgraded AK Steel (NYSE: AKS) to Buy.
    Craig-Hallum upgraded LendingClub (NYSE: LC) to Buy.
    Deal Talk

    General Electric (NYSE: GE) was said to be in talks to acquire Baker Hughes (NYSE: BHI), according to sources as reported by Dow Jones. A deal could be valued at as much as $30 billion. However, Bloomberg later reported that a GE spokesperson said they're in talks with Baker Hughes regarding possible partnerships, but not an acquisition. Halliburton (NYSE: HAL) had attempted to acquire Baker Hughes in 2014, but the DoJ sued to block the deal valued at $35 billion.

  • [By Lee Jackson]

    Another hedge fund that is also a director at Brink’s Co. (NYSE: BCO) was busy selling stock this past week. Starboard parted with a total of 650,000 shares of the security and protection company at prices that fell between $51.47 and $52.05. The total for the sale was set at $34 million. Shares closed on Friday at $52.00. The consensus price target is $56, and the52-week range is $26.86 to $53.90.

Top 10 Stocks To Watch For 2018: Axsome Therapeutics, Inc.(AXSM)

Advisors’ Opinion:

  • [By Lisa Levin]

    Axsome Therapeutics Inc (NASDAQ: AXSM) shares dropped 18 percent to $3.62. Axsome Therapeutics priced 3.74 million shares at $3.74 per share.

    Shares of Canadian Solar Inc. (NASDAQ: CSIQ) were down around 11 percent to $12.10 after the company posted downbeat quarterly earnings and issued a weak forecast.

  • [By William Romov]

    Currently trading at $4.85, Manhattan-based Axsome Therapeutics Inc. (Nasdaq: AXSM) makes drugs to treat depression, Alzheimer’s disease, and chronic pain.

  • [By Jim Robertson]

    On Tuesday, ourUnder the Radar Moversnewsletter suggested shorting small cap clinical-stage biopharmaceutical stock Axsome Therapeutics (NASDAQ: AXSM):

  • [By Paul Ausick]

    Axsome Therapeutics Inc. (NASDAQ: AXSM) traded down about 43% Tuesday and posted a new 52-week low of $3.20 after closing Monday at $5.55. The 52-week high is $6.45. Volume was about 3.8 million, about 19 times the daily average of around 220,000 shares. The company will stop a “futile” portion of a trial of its treatment for knee osteoarthritis.

Top 10 Stocks To Watch For 2018: Luby's, Inc.(LUB)

Advisors’ Opinion:

  • [By Monica Gerson]

    Luby’s, Inc. (NYSE: LUB) is expected to post earnings for the latest quarter.

    Simulations Plus, Inc. (NASDAQ: SLP) is estimated to post its quarterly earnings at $0.07 per share on revenue of $5.00 million.

Top 10 Stocks To Watch For 2018: Nu Skin Enterprises Inc.(NUS)

Advisors’ Opinion:

  • [By Craig Jones]

    Nu Skin Enterprises, Inc. (NYSE: NUS) is trading sharply higher on Friday, but options traders are buying puts in the name, said Jon Najarian. Traders were buying the June 50 puts and they paid around 6 percent for them, so they don't see much upside in Nu Skin Enterprises, explained Najarian. He followed the trade and he is planning to hold the position for a month.

  • [By Roberto Pedone]

    Nu Skin Enterprises (NUS) is a direct selling company, which develops and distributes personal care products and nutritional supplements that are sold under the Nu Skin and Pharmanex brands. This stock closed up 5.4% at $92.96 in Monday’s trading session.

    Monday’s Volume: 2 million

    Three-Month Average Volume: 900,802

    Volume % Change: 85%

    From a technical perspective, NUS ripped higher here right above some near-term support at $85 with heavy upside volume. This move pushed shares of NUS into breakout and new 52-week-high territory, since the stock took out some near-term overhead resistance levels at $88.20 to $89.69. This move also pushed shares of NUS above the upper-end of its recent range that saw the stock trend between $82 to just above $89.

    Traders should now look for long-biased trades in NUS as long as it’s trending above support at $85 and then once it sustains a move or close above Monday’s high of $93.33 with volume that this near or above 900,802 shares. If we get that move soon, then NUS will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $100 to $105.

  • [By Scott Rubin]

    Stock gainers included Mercadolibre Inc (NASDAQ: MELI), up almost 14 percent, and Nu Skin Enterprises, Inc. (NYSE: NUS), which added 12 percent. The positive gains in both stocks were due to strong earnings reports. Shares of Liberty Interactive Group (NASDAQ: QVCA) plunged almost 22 percent on Friday due to disappointing sales growth in its fiscal second quarter. Pharmaceutical giant Bristol-Myers Squibb Co (NYSE: BMY) lost 16 percent after a disappointing study involving its Opdivo drug.

  • [By Ben Levisohn]

    Citigroup’s Beth Kite calls Nu Skin Enterprises’ (NUS) earnings and guidance “awfully disappointing.” She explains why:

    “Frustrating” Describes 4Q15 & 2016 Guidance:Nu Skin (i) reported 4Q15 EPS of $0.62, 11 cents below consensus and us, and (ii) lowered 2016 EPS guidance, from $3.25-$3.40 to $2.40-$2.60.Nu Skin had three LTO’s in 4Q152 succeeded and 1 failed. The failure had far less to do with the product than with the sales strategy…

    Is Guidance Too Conservative or Is It Really This Bad? We get that Me failed to sell well in South Korea with the 12-month cartridge commitment. But given the strength in reps globally, the strength of Youth from its two LTOs in 2H15, and good results from Me when sold in Japan without the 12-month commitment, we wonder if guidance is aggressive to the downside. Indeed, the word “conservative” was said a lot by mgmt on the brief earnings call when describing guidance revisions.

    Maintaining Buy: While we now have less confidence in mgmt, from an external perspective, to forecast its results accurately, and from an internal perspective, to course correct quicklyi.e., why didn’t they drop the 12-month plan for Me in South Korea when it so obviously wasn’t workingwe are still confident in Youth & Me. The rep growth in South Asia/Pacific from Youth in 3Q led to better 4Q sales than we’d expected, Youth’s Americas LTO in 4Q drove lc sales up 26% YoY, and Me not only sold through in Japan in 4Q but also drove reps higher. We imagine that investors may have little patience or confidence in Nu Skin for a while, understandably. But the bar seems set fairly low now, so we are cautiously optimistic that Nu Skin can dig itself out of this hole as we go through 2016 and Me & Youth roll out more fully.

    Shares of Nu Skin have tumbled 13% to $27.31 at 2:11 p.m. today.

Top 10 Stocks To Watch For 2018: Oak Valley Bancorp (CA)(OVLY)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Tuesday, financial shares fell 0.32 percent. Meanwhile, top losers in the sector included Oak Valley Bancorp (NASDAQ: OVLY), down 7 percent, and AmTrust Financial Services Inc (NASDAQ: AFSI) down 5 percent.

Top 10 Stocks To Watch For 2018: Corbus Pharmaceuticals Holdings, Inc.(CRBP)

Advisors’ Opinion:

  • [By Sean Williams]

    This rapid growth in legal pot has create quite the demand for marijuana stocks. The seven largest marijuana stocks by market cap have all put on a show over the past couple of years. Here are those seven “green giants” listed with their market caps as of March 17, 2017, along with their trailing one-year total returns.

    GW Pharmaceuticals (NASDAQ:GWPH): $3.0 billion, up 64% Canopy Growth Corp. (NASDAQOTH:TWMJF): $904 million, up 259% Aphria (NASDAQOTH:APHQF) $440 million, up 381% Aurora Cannabis (NASDAQOTH:ACBFF): $482 million, up 299% AXIM Biotechnologies (NASDAQOTH:AXIM): $562 million, up 1,720% Corbus Pharmaceuticals (NASDAQ:CRBP): $450 million, up 431% Medical Marijuana (NASDAQOTH:MJNA): $221 million, up 254%

    As you can see, these are some hefty valuations — and some exceptionally strong moves higher on the heels of marijuana’s expansion. With the exception of GW Pharmaceuticals, every one of the largest marijuana stocks has at least tripled in value over the trailing 12 months, with cannabinoid-based drug developer AXIM Biotechnologies skyrocketing more than 1,700%!

  • [By Keith Speights]

    Corbus Pharmaceuticals (NASDAQ:CRBP) managed to become one of the top-performing biotech stocks on the market in 2016. Over the last 12 months, Corbus’ share price has soared 550%.

Top 10 Stocks To Watch For 2018: Texas Roadhouse, Inc.(TXRH)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Texas Roadhouse Inc. (NASDAQ: TXRH) was raised to Buy from Neutral at BTIG Research.

    USG Corp. (NYSE: USG) was reiterated as Hold but the price target was raised to $35 from $29 (versus a $34.23 close) at Jefferies.

  • [By Joe Tenebruso]

    Fortunately, well-chosen dividend-growth stocks can help you accomplish both of these goals. And with its powerful wealth-building combination of increasing dividend payouts and share-price appreciation, Texas Roadhouse (NASDAQ:TXRH)is one of the best available in the market today.

  • [By Teresa Rivas]

    Texas Roadhouse(TXRH) tumbled more than 12% on Wednesday as itsfourth-quarter earningsand revenue fell short of expectations.

    Pixabay

    The restaurant chain said it earned 29 cents a share on revenue of $484.7 million. Analysts were expecting earnings per share of 38 cents on revenue of $497.3 million.

    Same-restaurant sales grew 1.2% at company restaurants and 2% at domestic franchises. For the first 55 days of the first quarter, Texas Roadhouse said that same-store sales rose 1.5%.

    The company also raised its dividend 10.5% to 21 cents a share.

    Some analysts urged investors to keep the faith in the stock.Barclay’s JeffreyBernsteinreiterated an Overweight rating and $47 price target on thestock:

    We believe TXRH fundamentals remain best-in-class. That said, the near-term focus remains on directional comps. And not unlike the broader industry, TXRH comps eased significantly to close 2016. Such led to disappointing 4Q16 results from top to bottom. Importantly, while the brand ‘is not immune’ to industry comp headwinds, the relative outperformance to the category was maintained. Looking to 2017, key guidance metrics were reiterated. While questions remain on whether the recent easing of industry comps will persist, we remain comforted by TXRH’s relative outperformance and easing comps as we move through 2017.

    Maxim’s Stephen Andersonreiterated a Buy rating, although he took his price target down $4, to $52:

    In our view, TXRH is not immune to the broader slowdown in Casual Dining, but we believe the company will emerge stronger than peers in the next few quarters.TXRHs disappointing 4Q16 comp of +1.3% (blended) was pulled down by a rare negative comp month in December (-2.1%), marking the first time this occurred in almost four years. Comps were +3% or better in both October and November, and comps so far in 1Q17 are positive despite a stormy start to the quarter in

  • [By Dan Caplinger]

    Steakhouse chain Texas Roadhouse (NASDAQ:TXRH) has had to deal with an extremely difficult business environment for restaurant companies, and investors know all too well how tough times can hurt major players in the industry. Last quarter, Texas Roadhouse disappointed investors with sluggish results, and the company wanted to start 2017 on a better footing.

  • [By Demitrios Kalogeropoulos]

    As for individual stocks, Texas Roadhouse (NASDAQ:TXRH) and Garmin (NASDAQ:GRMN)made large moves following their quarterly earnings announcements.

5 Top Biotech Penny Stocks to Buy with Huge Catalysts in January 2018

Few investments have the profit potential of penny stocks, which are stocks that trade under $5 per share.

Just take a look at Marathon Patent Group Inc. (Nasdaq: MARA), which climbed an astounding 341% during the four trading days of Thanksgiving week.

Biotech penny stocks are especially attractive since successful clinical trial results for their drugs can often send their share prices soaring 300%-plus.

That’s why today we’re giving you five of the top biotech penny stocks to buy that are all reporting clinical trial results in January 2018.

If a stock’s clinical trial results are positive, then the stock can soar. For example, the first stock on this list shot up 213% in July after the U.S. Food and Drug Administration (FDA) accepted the resubmission of its New Drug Application (NDA) for one of its drugs.

Receiving FDA approval for an NDA is typically the last major benchmark a drug must pass before it can be launched.

While these stocks have huge profit potentials, you must keep in mind that penny stocks are very speculative investments. They often see big pullbacks after making large gains.

That’s why Money Morning recommends that no more than 2% of your stock portfolio consist of such risky investments.

But if you’re willing to take the risk, some of these stocks could bring you profits of over 300% next year.

FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, it’s completely free…

Now get comfy and grab your calendar, because here’s the first biotech penny stock on our list today…

Biotech Penny Stocks to Buy for January, No. 5: Aeterna Zentaris Inc.

Currently trading at $2 per share, Aeterna Zentaris (Nasdaq: AEZS) makes the drug Macrilen as a potential treatment for growth hormone deficiency in adults.

On July 18, the company announced the FDA accepted its NDA for Macrilen for review. This news sent AEZS shares up from $1.02 to $3.20 in just three trading days, for a gain of 213%.

top biotech penny stocks to buymoneymorning.com/wp-content/blogs.dir/1/files/2017/12/spilling-medicine-75×113.png 75w, moneymorning.com/wp-content/blogs.dir/1/files/2017/12/spilling-medicine.png 300w” sizes=”(max-width: 200px) 100vw, 200px” title=”top biotech penny stocks to buy” />

Still, before Aeterna can launch the drug Macrilen, its resubmitted NDA must be approved by the FDA. The FDA will announce if it approves Aeterna’s resubmitted NDA on Dec. 30.

Company officials are confident the company will be able to launch Macrilen sometime in the first quarter of 2018.

Keep an eye on AEZS shares leading up to the Dec. 30 announcement, and buy only if you believe the FDA will approve the NDA.

Up next is a stock with a drug that has three chances to pass phase 3 clinical trials…

Biotech Penny Stocks to Buy for January, No. 4: Axsome Therapeutics Inc.

Currently trading at $4.85, Manhattan-based Axsome Therapeutics Inc. (Nasdaq: AXSM) makes drugs to treat depression, Alzheimer’s disease, and chronic pain.

Unlike other biotech penny stocks, shares of AXSM aren’t “all in” on just one drug’s results.

Axsome has at least three different drugs in clinical trial testing, meaning it has a greater chance of having at least one of its drugs pass. This makes shares of AXSM less risky than a biotech penny stock with only one drug in development.

Specifically, we’re going to focus on Axsome’s AXS-02 drug, which is in two separate phase 3 clinical trials to treat complex regional pain syndrome and knee osteoarthritis associated with bone marrow lesions. The results for these two clinical trials are expected in late December or early January.

VideoMeet the Trading Expert Who Could Help Make You a Millionaire

If the AXS-02 drug passes phase 3 clinical trials, the stock could jump significantly.

The company also has a second drug, AXS-05, currently in phase 3 clinical trials for the treatment of treatment-resistant depression. Those results are expected sometime in the first half of 2018, so it’s likely that AXS-02’s results will come out first.

The next company we’ll show you is the cheapest on this list…

Biotech Penny Stocks to Buy for January, No. 3: BioLine Rx Ltd.

Currently trading at $1.09 per share, BioLine Rx Ltd. (Nasdaq: BLRX) develops a broad range of drug candidates to treat cancer, liver fibrosis, and even dry eye syndrome.

BioLine has partnerships with major pharmaceutical companies that help bring some of these drugs to launch once they gain some initial success in clinical trials. These partners include Novartis AG (NYSE: NVS) and Merck & Co. Inc. (NYSE: MRK).

Like Axsome Therapeutics, BioLine is less risky than other biotech penny stocks that only have a single drug in development or single partner. But BioLine’s risk profile is even more diverse, with eight drugs in development and multiple major partnerships to help support it.

The company’s leading drug BL-8040 is being tested in three different phase 2 clinical trials in 2018. The first trial is for the drug’s treatment of pancreatic cancer. Partial data of the trial will be presented between Jan. 18 and 20 at the ASCO 2018 Gastrointestinal Cancers Symposium.

Next up is a company which makes a drug that could provide millions of Americans with the relief they so deserve…

Join the conversation. Click here to jump to comments…

how to invest in the stock market

Bob Rodriguez: Trump Might Be Acting; Huge Financial Crisis Still Looming

15 Worst States for Retirement: 2017

Major Risks Are Looming for US Economy: Merrills Ethan Harris

Raymond James says a group of four advisors has joined its employee channel from Morgan Stanley with about $5 million in yearly fees and commissions and $460 million in client assets.

The four registered reps joining it in Mr. Laurel, New Jersey, now do business as SSG Executive Advisory Group of Raymond James, which includes Todd Sherman, CIMA; Jason Sobin; Michael Francisco; and Brian Baskin, CFP.

The firm says its more than 7,100 indie and employee reps will have access to the innovations by year-end.

You are signed up!

ThinkAdvisor’s TechCenter is an educational resource designed to give you a competitive edge by keeping you abreast of new tech innovations and need-to-know information that can be applied to your business. Resources STRAIGHT-THROUGH PROCESSING FOR THE FINANCIAL SERVICES INDUSTRY

STP can be described as electronically capturing and processing transactions in one pass, from the point of first ‘deal’ to final settlement.

how to invest in the stock market: Monro Muffler Brake, Inc.(MNRO)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Yesterday, shares of Monro Muffler Brake (MNRO) plunged 3.1% after Barron’s Leslie Norton panned the stock in this weekend’s issue of the magazine. And wouldn’t you know it? Monro’s shares are skidding lower once again today.

    Mike Mozart/JeepersMedia

    Norton’s argument was straightforward:

    At a recent $62, Rochester, N.Y.based Monro (ticker: MNRO) trades at a lofty 28 times forward earnings, compared with a 10-year average of 21.1, and 17 times earnings for the Standard & Poors 500. With sales growth slowing as competition increases, Monros strategic goal of achieving 15% annual sales gains and 20% profit growth seems distant.

    Any hint of more sluggish sales could push the shares down at least 10%. Bruce Geller, CEO of money manager Dalton Greiner Hartman Maher, who is short the stock, says, A fairly commoditized business with low organic growth deserves a more reasonable multiple of 20 times.

    That would put the stock in the mid-$40s.

    Shares of Monro Muffler Brake have dropped 4% to $57.59 at 3:49 p.m. today, leaving around 20% of downside.

    UPDATE: This post initially misspelled ‘Brake’ as ‘Break.’ It’s been corrected.

how to invest in the stock market: Mayne Pharma Group Limited (MAYNF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    We believe that two main risks currently exist. First, a few days ago, U.S. Department of Justice filed charges in generic drug price-fixing probe. The U.S. Department of Justice accused two former generic pharmaceutical executives of colluding with other generic manufacturers to fix prices – the first criminal charges stemming from a two-year investigation. Companies in the congressional probe have since publicly disclosed that they have received subpoenas, including Mylan NV (NASDAQ:MYL), Allergan (NYSE:AGN), which later sold its generics business to Teva (NASDAQ:TEVA), Lannett (NYSEMKT:LCI), Impax Laboratories (NASDAQ:IPXL), Endo International (NASDAQ

where to buy penny stocks

North Korea’s rapid development of missile technology comes from an unexpected source…

The Ukraine.

Evidence of this connection was first revealed on Aug. 14 in a report by the International Institute for Strategic Studies (IISS).

The IISS report claimed that Pyongyang’s recent success with intercontinental ballistic missiles (ICBMs) was facilitated by black market purchases of foreign rocket engines and intellectual property.

And evidence to further support the IISS’ claim surfaced just this week…

North Korean Media Let Slip the Country’s Latest Rocket Designs

On Tuesday, North Korean state media released images of dictator Kim Jong Un with what looked like cutting-edge rocket engine designs hung on the walls around him.

Indeed, the isolated regime has made leaps and bounds in its missile and rocket engine technology in recent months, dating back to August 2016 in particular…

Don’t Miss: Trump’s Secret Weapon Set to Foil China’s Master Plan

where to buy penny stocks: Calavo Growers, Inc.(CVGW)

Advisors’ Opinion:

  • [By Shanthi Rexaline]

    Agricultural Produce Companies

    Limoneira Company (NASDAQ: LMNR): -32.1 percent since 2011. Calavo Growers, Inc. (NASDAQ: CVGW): +168.2 percent since 2011.

    Agri-Input Companies — Seeds/ Fertilizers/Pesticides Manufacturers

  • [By Lee Jackson]

    Calavo Growers Inc. (NASDAQ: CVGW) had the man at the top buying stock last week. CEO Lecil Cole purchased 95,000 shares of the avocados and other perishable foods distributor at prices between $55.44 and $56.92 a share. The total for the purchase was set at $5 million. The stock closed the day last Friday at $58.30, in a52-week range of$48.745 to $71.48. The consensus price target is set at $73.17.

where to buy penny stocks: Molex Incorporated(MOLX)

Advisors’ Opinion:

  • [By Shauna O’Brien]

    Shares of electronic connector maker Molex Incorporated (MOLX) skyrocketed on Monday morning after reports that the company will be acquired by Koch Industries.

    Koch Industries has agreed to acquire Molex for a total of $7.2 billion. This deal will include all outstanding shares of the company’s Common Stock, Class A Common Stock and Class B Common Stock for $38.50 per share.

    The deal has been approved by the board of directors of both companies. Molex will continue to maintain its current management team and its current headquarters in Lisle, IL.

    Molex shares were up $9.15, or 31.17%, during Monday morning trading. The stock is up 41% YTD.

where to buy penny stocks: Outerwall Inc.(OUTR)

Advisors’ Opinion:

  • [By Monica Gerson]

    Shares of Outerwall Inc (NASDAQ: OUTR) surged over 8 percent in Monday’s after-hours trading session following news for investors the company has begun the process of exploring strategic and financial alternatives. Outerwall’s Board also announced the raising of the company’s quarterly dividend from $0.30 to $0.60 per share. Outerwall shares jumped 8.11 percent to $37.18 in the after-hours trading session.

  • [By Monica Gerson]

    Outerwall (NASDAQ: OUTR) dipped 19.33% to $45.15 in the pre-market session after the company lowered its forecast for the third quarter and full year.

  • [By Lisa Levin]

    Outerwall (NASDAQ: OUTR) plummeted 12.08% to $49.21 after the company lowered its forecast for the third quarter and full year.

    JinkoSolar Holding Co (NYSE: JKS) dropped 9.88% to $16.87 after the company announced the offering of 3,500,000 American Depositary Shares.

  • [By Monica Gerson]

    Outerwall (NASDAQ: OUTR) lowered its forecast for the third quarter and full year. Outerwall shares dipped 19.96% to $44.80 in after-hours trading.

where to buy penny stocks: Axsome Therapeutics, Inc.(AXSM)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Tuesday, ourUnder the Radar Moversnewsletter suggested shorting small cap clinical-stage biopharmaceutical stock Axsome Therapeutics (NASDAQ: AXSM):

  • [By Lisa Levin]

    Axsome Therapeutics Inc (NASDAQ: AXSM) shares dropped 18 percent to $3.62. Axsome Therapeutics priced 3.74 million shares at $3.74 per share.

    Shares of Canadian Solar Inc. (NASDAQ: CSIQ) were down around 11 percent to $12.10 after the company posted downbeat quarterly earnings and issued a weak forecast.

where to buy penny stocks: Peregrine Pharmaceuticals Inc.(PPHM)

Advisors’ Opinion:

  • [By Alex McGuire]

    Here’s a list of the top 10 penny stocks to watch in March, which includes the biggest gainers last month…

    Penny StockCurrent Stock PriceFebruary 2017 ReturnZosano Pharma Corp. (Nasdaq: ZSAN)$2.56+123.3%Bellerophon Therapeutics Inc. (Nasdaq: BLPH)$1.25+113.8%Peregrine Pharmaceuticals (Nasdaq: PPHM)$0.59+101.7%Galectin Therapeutics Inc. (Nasdaq: GALT)$1.79+91.9%Bioanalytical Systems Inc. (Nasdaq: BASI)$1.58+90.6%CymaBay Therapeutics Inc. (Nasdaq: CBAY)$3.50+89.8%Vermillion Inc. (Nasdaq: VRML)$2.56+86.3%Naked Brand Group Inc.(Nasdaq:NAKD)$2.16+76%Eyegate Pharmaceuticals Inc. (Nasdaq: EYEG)$2.63+73.9%Benitec Biopharma Ltd. (Nasdaq ADR: BNTC)$2.60+59.9%

    The best-performing penny stock – Zosano Pharma Corp. – soared an incredible 123.3% from Feb. 1 to Feb. 28. To put those gains into perspective, that’s more than five times the S&P 500’s 23% climb in the last 12 months.

where to buy penny stocks: Six Flags Entertainment Corporation New(SIX)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Cara Therapeutics (CARA) , Verizon (VZ) , Radius Health (RDUS) and Six Flags (SIX) .

    Cramer was bearish on Hertz Global Holdings (HTZ) , General Motors (GM) , Pandora Media (P) , Cedar Fair (FUN) , Quotient Technology (QUOT) and Rite Aid (RAD) .

  • [By Lee Jackson]

    Six Flags Entertainment Inc. (NYSE: SIX) also recently had a large buyer acquiring more shares of the company. CEO and the President John Duffey bought a total of 25,000 shares of the theme park giant at $59.93 per share. The total for the trade was posted at $1,498,198. The stock closed last Friday at $59.96. The 52-week range for the shares is $45.24 to $62.69. The consensus price target is $62.43.

  • [By WWW.THESTREET.COM]

    That’s not to say the consumer never leaves the house, but when they do, they shop for their homes at Home Depot (HD) and Home Goods, the TJX Stores (TJX) chain that’s knocking it out of the park. The consumer is also visiting theme parks like Six Flags (SIX) and Walt Disney (DIS) and they’re also going on Carnival Cruises (CCL) .

  • [By WWW.THESTREET.COM]

    All is not lost for retail, however. Cramer continued to recommend the closeout and discount chains like TJX Stores (TJX) , Ollie’s Bargain Outlet (OLLI) and Burlington Stores (BURL) . He was also bullish on those who cater to the millennials, like Six Flags (SIX) , Dave & Busters (PLAY) and Foot Locker (FL) , where trying on shoes never seems to go out of style.